Shanghai Henlius Biotech Inc. has announced preclinical data showing that its small-molecule drug HLX-99 exhibited antineurodegenerative activities in multiple models, warranting further development.

The CMT Research Foundation has formed a strategic partnership with Revir Therapeutics Inc. to advance small-molecule therapeutics that modulate the expression of the gene that causes Charcot-Marie-Tooth disease type 1A (CMT1A).

Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.

Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.

The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.